Table 2.
SARS-CoV-2 course of infection of LC and non-LC cohorts
| Survey responders (n = 175) | LC (n = 115) | Non-LC (n = 60) | p | OR (95% CI) |
|---|---|---|---|---|
| Unvaccinated (%) | 31 (27) | 12 (21.7) | 0.303 | 1.50 (0.69–3.27) |
| Vaccination status 3 doses (%) | 59 (51.3) | 31 (51.7) | 0.325 | 0.70 (0.35–1.42) |
| Vaccination status 4 doses (%) | 17 (14.8) | 12 (20) | 0.380 | 0.69 (0.31–1.57) |
| Median days of infection (IQR) | 18 (11–23.5) | 13 (8–22) | 0.029 | 1.02 (0.99–1.05) |
| Wuhan + alpha | 25 (21.7) | 8 (13.3) | 0.181 | 1.81 (0.76–4.29) |
| Delta | 7 (6.1) | 3 (5) | 0.769 | 1.23 (0.31–4.94) |
| Omicron (%) | 83 (72.2) | 50 (83.3) | 0.104 | 0.52 (0.23–1.15) |
| Antiviral (%) | 37 (32.2) | 17 (28.3) | 0.602 | 1.20 (0.60–2.38) |
| mAb (%) | 46 (40) | 19 (31.7) | 0.280 | 1.44 (0.74–2.78) |
| Antiviral + mAb (%) | 78 (67.8) | 36 (60.0) | 0.303 | 1.41 (0.73–2.69) |
| Mild (%) | 104 (90.4) | 59 (98.3) | 0.050 | 0.16 (0.02–1.27) |
| Moderate-severe (%) | 12 (9.6) | 1 (1.7) | 0.050 | 6.24 (0.79–49.51) |
| Reinfections (%) | 26 (22.6) | 11 (18.3) | 0.510 | 1.30 (0.59–2.86) |
| ICU (%) | 2 (1.7) | 1 (1.6) | 0.972 | 1.04 (0.93–11.8) |
| Complication during COVID-19 | ||||
| Hospitalization (%) | 12 (9.6) | 1 (1.7) | 0.050 | 6.24 (0.79–49.51) |
| PTE (%) | 1 (0.9) | 0 | 1.000 | 1.59 (0.64–39.5) |
| Bacterial superinfection (%) | 6 (5.2) | 1 (1.7) | 0.255 | 3.25 (0.38–27.6) |
Statistically significant results in bold